Want to see IN:SURAKSHA full AI Analyst Report?

Suraksha Diagnostic Ltd. (SURAKSHA) Price & Analysis

2 Followers

SURAKSHA Stock Chart & Stats

₹300.85

-₹13.40(-3.48%)

At close: Jan 08 4:00 PM EST

₹300.85

-₹13.40(-3.48%)

Day’s Range― - ―

52-Week Range₹224.10 - ₹333.65

Previous CloseN/A

Volume140.52K

Average Volume (3M)1.23K

Market Cap

₹13.11B

Enterprise Value₹16.27K

Total Cash (Recent Filing)₹263.48M

Total Debt (Recent Filing)₹1.30B

Price to Earnings (P/E)40.8

Beta1.08

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)6.18

Shares Outstanding52,080,757

10 Day Avg. Volume1,073

30 Day Avg. Volume1,225

Financial Highlights & Ratios

PEG Ratio32.20

Price to Book (P/B)4.85

Price to Sales (P/S)3.82

P/FCF Ratio70.61

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)9.2

Revenue Forecast (FY)₹3.68B

Bulls Say, Bears Say

Bulls Say

Revenue And Operating ProfitabilityMulti-year revenue growth (healthy rebound after FY23; ~15% in FY24–FY25 and ~12.5% in FY26) with sustained operating margin (~17.5%) and strong EBITDA (~30.9%) indicates a resilient service model. This scale and margin provide durable cash generation and room to reinvest in network expansion and quality improvements over the medium term.

Operating Cash Generation QualityOperating cash flow exceeding reported net income (~1.41x) signals earnings quality and core cash generation strength. Reliable operating cash helps fund working capital and capex needs internally, reducing reliance on external financing and supporting steady operations and growth execution over several quarters.

Manageable Balance-sheet Leverage And ScaleA moderate debt-to-equity (~0.53) with growing asset and equity base suggests the company has room to finance expansion while maintaining financial flexibility. The improving scale reduces unit costs and strengthens bargaining power with suppliers, supporting sustainable operations and investment capacity in the medium term.

Bears Say

Margin Compression And VolatilitySharp FY26 gross and net margin declines point to persistent cost, pricing, or mix pressures that can erode durable profitability. Continued margin volatility reduces predictable free cash generation, complicates planning for reinvestment or deleveraging, and raises the bar for operational improvements to restore longer-term return levels.

Rising Leverage TrendAn upward drift in debt since FY25 increases financial risk even if current leverage is moderate. Persistently rising indebtedness limits strategic flexibility, raises interest-cost sensitivity, and can constrain capital allocation choices during economic stress or to seize growth opportunities over the next several quarters.

Weak Free-cash-flow ConversionLow FCF conversion (~20% of net income) despite strong operating cash flow suggests heavy capex or working-capital absorption. Weak, volatile FCF limits ability to pay down debt, sustain dividends, or self-fund growth without external funding, creating a structural constraint on long-term financial flexibility.

Suraksha Diagnostic Ltd. News

Suraksha Diagnostic’s Company Secretary and Compliance Officer Resigns

Suraksha Diagnostic Ltd. ( ($IN:SURAKSHA) ) has issued an update. Suraksha Diagnostic Limited has announced that Ms. Mamta...

2M ago

Suraksha Diagnostic Closes Trading Window Ahead of FY26 Results

An announcement from Suraksha Diagnostic Ltd. ( ($IN:SURAKSHA) ) is now available. Suraksha Diagnostic Limited has notified the...

5M ago

Suraksha Diagnostic CFO K S Ravindra to Step Down by May 31, 2026

Suraksha Diagnostic Ltd. ( ($IN:SURAKSHA) ) has issued an update. Suraksha Diagnostic Limited has announced that Group Chief...

5M ago

Suraksha Diagnostic Announces Trading Window Closure

Suraksha Diagnostic Ltd. ( ($IN:SURAKSHA) ) just unveiled an announcement. Suraksha Diagnostic Limited has announced the closure of...

11M ago

Suraksha Diagnostic to Present Q1 Financial Results in Upcoming Earnings Call

Suraksha Diagnostic Ltd. ( ($IN:SURAKSHA) ) has provided an update. Suraksha Diagnostic Limited announced an upcoming Investor Presentation...

12M ago

Suraksha Diagnostic Ltd. Releases Unaudited Financial Results

Suraksha Diagnostic Ltd. ( ($IN:SURAKSHA) ) just unveiled an update. Suraksha Diagnostic Ltd. has published its unaudited financial...

1y ago

SURAKSHA FAQ

What was Suraksha Diagnostic Ltd.’s price range in the past 12 months?

Suraksha Diagnostic Ltd. lowest stock price was ₹224.10 and its highest was ₹333.65 in the past 12 months.

What is Suraksha Diagnostic Ltd.’s market cap?

Suraksha Diagnostic Ltd.’s market cap is ₹13.11B.

When is Suraksha Diagnostic Ltd.’s upcoming earnings report date?

Suraksha Diagnostic Ltd.’s upcoming earnings report date is Aug 07, 2026 which is tomorrow.

How were Suraksha Diagnostic Ltd.’s earnings last quarter?

Suraksha Diagnostic Ltd. released its earnings results on May 21, 2026. The company reported ₹1.21 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Suraksha Diagnostic Ltd. overvalued?

According to Wall Street analysts Suraksha Diagnostic Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Suraksha Diagnostic Ltd. pay dividends?

Suraksha Diagnostic Ltd. pays a N/A dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Suraksha Diagnostic Ltd. dividends here

What is Suraksha Diagnostic Ltd.’s EPS estimate?

Suraksha Diagnostic Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Suraksha Diagnostic Ltd. have?

Suraksha Diagnostic Ltd. has 52,080,757 shares outstanding.

What happened to Suraksha Diagnostic Ltd.’s price movement after its last earnings report?

Suraksha Diagnostic Ltd. reported an EPS of ₹1.21 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.73%.

Which hedge fund is a major shareholder of Suraksha Diagnostic Ltd.?

Currently, no hedge funds are holding shares in IN:SURAKSHA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Suraksha Diagnostic Ltd.

Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping; and radiology testing that includes X ray, magnetic resonance imaging, computed tomography scan, USG, DEXA scan, OPG, and mammography. The company also provides Cardiology testing services comprises electrocardiogram, echocardiogram, stress test / treadmill test, wireless holter monitoring, colour doppler, peripheral doppler, and pulmonary function test; gastroenterology, such as upper and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy; and neurology testing services, including electroencephalogram, electromyography, and nerve conduction velocity test. In addition, the company provides dental, physiotherapy, immunology & rheumatology, eye, fetal care, ENT, and speciality clinics, as well as home doctor visit services. The company was founded in 1992 and is based in Kolkata, India.